Literature DB >> 12115839

Formulation pH modulates the interaction of insulin with chitosan nanoparticles.

Zengshuan Ma1, Hock Hin Yeoh, Lee-Yong Lim.   

Abstract

Previous studies on chitosan-insulin nanoparticles have reported diverse encapsulation efficiency and insulin release profiles despite similar formulation and preparation procedures. This study examined the efficiency and mechanism of association of insulin with chitosan nanoparticles in the pH range of 2.3 to 6.3. Nanoparticles of 237 to 235 nm were prepared by ionotropic gelation of chitosan with tripolyphosphate counterions. Insulin was quantified by an RP-HPLC method. The insulin association efficiency (AE) spanned a broad range from 2 to 85%, and was highly sensitive to formulation pH. Highest AE was measured at insulin loading concentrations >/= 4.28 U/mL and pH 6.1, close to the pI of native insulin and the pK(a) of chitosan. This association, attributed to physical adsorption of insulin through hydrophobic interactions with chitosan, was labile, and the associated insulin rapidly and completely released by dilution of the nanoparticles in aqueous media of pH 2 to 7.4. AE obtained at pH 5.3 was less than half that measured at pH 6.1 at corresponding insulin concentration, but the association at pH 5.3 appeared to be based on stronger interactions, because the release of insulin was pH-dependent and recovery was less than 25% even upon disintegration of the chitosan matrix. Interaction of insulin with the chitosan nanoparticles rendered the protein more susceptible to acid and enzymatic hydrolyses, the effects being more predominant in nanoparticles prepared at pH 5.3 than at pH 6.1. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115839     DOI: 10.1002/jps.10149

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  21 in total

1.  Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles.

Authors:  Zengshuan Ma; Lee-Yong Lim
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

Review 2.  Recent advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents.

Authors:  Anumita Chaudhury; Surajit Das
Journal:  AAPS PharmSciTech       Date:  2010-12-11       Impact factor: 3.246

Review 3.  Detecting and treating cancer with nanotechnology.

Authors:  Keith B Hartman; Lon J Wilson; Michael G Rosenblum
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

4.  IGF-1 release kinetics from chitosan microparticles fabricated using environmentally benign conditions.

Authors:  Venkata P Mantripragada; Ambalangodage C Jayasuriya
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2014-06-07       Impact factor: 7.328

5.  Chitosan-sodium lauryl sulfate nanoparticles as a carrier system for the in vivo delivery of oral insulin.

Authors:  Amani Elsayed; Mayyas Al-Remawi; Nidal Qinna; Asim Farouk; Khaldoun A Al-Sou'od; Adnan A Badwan
Journal:  AAPS PharmSciTech       Date:  2011-07-15       Impact factor: 3.246

Review 6.  Chitin and chitosan: biopolymers for wound management.

Authors:  Rita Singh; Kirti Shitiz; Antaryami Singh
Journal:  Int Wound J       Date:  2017-08-10       Impact factor: 3.315

7.  Insulin therapies: Current and future trends at dawn.

Authors:  Subhashini Yaturu
Journal:  World J Diabetes       Date:  2013-02-15

8.  Tetanus toxoids loaded glucomannosylated chitosan based nanohoming vaccine adjuvant with improved oral stability and immunostimulatory response.

Authors:  Harshad Harde; Ashish Kumar Agrawal; Sanyog Jain
Journal:  Pharm Res       Date:  2014-07-17       Impact factor: 4.200

9.  Preparation of chitosan-hyaluronate double-walled microspheres by emulsification-coacervation method.

Authors:  Fengxia Liu; Lingrong Liu; Xuemin Li; Qiqing Zhang
Journal:  J Mater Sci Mater Med       Date:  2007-08-15       Impact factor: 3.896

10.  Formulation and targeting efficiency of Cisplatin engineered solid lipid nanoparticles.

Authors:  R C Doijad; F V Manvi; D M Godhwani; R Joseph; N V Deshmukh
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.